Kenvue Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KVUE research report →
Range $19 – $20
Price Chart
About the company
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health.
- CEO
- Kirk L. Perry
- IPO
- 2023
- Employees
- 21,890
- HQ
- Summit, NJ, US
AI snapshot
Six angles, distilled from the data.
The stock is still in a recovery phase, but the longer-term trend remains mixed. It sits below its 200-day average of 18.03 and 50-day average of 18.67, yet well above the 52-week low of 13.22, suggesting a base-building regime rather than a clean uptrend.
Street sentiment is cautious-to-neutral, with a Hold consensus and a $19.50 target versus the last close at 17.22. Recent changes have mostly been reaffirmations, while Jefferies cut its view to Hold in January, keeping the overall tone measured rather than bullish.
The company has a solid recent beat pattern, going 5-for-7 on EPS, including two straight beats before the last quarter missed by 3.1%. Next-year EPS is modeled at 1.2398 versus 0.83 TTM, so shareholders should watch whether margin discipline can keep that trajectory intact.
The signal is mixed, with one discretionary sale from the CFO & CAO and no offsetting open-market buys. Most other activity is award, vesting, or exemption-related grants, which reads as routine compensation flow rather than a strong directional insider message.
Profitability is healthy for a consumer staples name, with a 58.4% gross margin, 19.42% operating margin, and 10.76% net margin. Revenue grew 3.0% year over year and earnings grew 8.5%, while free cash flow reached $2.672 billion, supporting an 8.08% FCF yield.
KVUE looks steadier than a cyclical consumer name, but it carries a heavier debt load with $8.524 billion of total debt against $1.062 billion of cash. At 14.59x earnings, it trades at a modest valuation for consumer staples, with the setup favoring cash generation over growth.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $33.39B
- P/E
- 19.99
- Fwd P/E
- 14.79
- PEG
- 1.14
- P/S
- 2.17
- P/B
- 3.16
- EV/EBITDA
- 12.87
- Div Yield
- 5.99%
- Gross Margin
- 58.19%
- Op Margin
- 19.52%
- Net Margin
- 10.76%
- ROE
- 15.58%
- ROIC
- 10.07%
Latest fiscal year · YoY change
- Revenue
- $15.12B-2.1%
- Gross Profit
- $8.79B-1.9%
- Op Income
- $2.70B
- Net Income
- $1.47B+42.7%
- EPS
- $0.77+42.6%
- OCF Growth
- +24.2%
- FCF Growth
- +29.0%
- 52W High
- $20.13
- 52W Low
- $14.02
- 50D MA
- $18.64
- 200D MA
- $18.03
- Beta
- 0.43
- RSI (14)
- 36
- Avg Volume
- 22.03M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Kenvue posted a weak second quarter and cut 2025 guidance, while management signaled an aggressive turnaround, tighter focus, and an active strategic review of alternatives.· August 7, 2025
- Organic sales fell 4.2%; adjusted operating margin was 22.7%, adjusted EPS was $0.29 versus $0.32 a year ago, and adjusted gross margin was 60.9%.
- Global consumption outpaced organic sales across all segments, but management said execution, inventory timing, and soft seasonal demand weighed on the quarter.
- The Board is pursuing a comprehensive review of strategic alternatives, including possible portfolio optimization, while the company also pushes immediate operating changes.
- Management highlighted self-induced complexity: 115 brands, but 41 drive over 3/4 of sales; the long tail of SKUs contributes about 1% of sales.
- Full-year 2025 guidance was cut to low-single-digit organic sales decline, adjusted operating margin down versus last year, and adjusted EPS of $1.00 to $1.05.
- Tariffs are now expected to carry about a $150 million annualized gross impact, though below that in 2025 due to timing.
Second-quarter organic sales declined 4.2%. Adjusted gross margin contracted 70 basis points to 60.9%, adjusted operating margin contracted 10 basis points to 22.7%, and adjusted diluted EPS was $0.29 versus $0.32 a year ago. Adjusted net income was $560 million, and below-the-line items were unfavorable year over year, with net interest expense up about $2 million to $94 million and the adjusted tax rate at 26.9% versus 25.7%. For 2025, Kenvue now expects organic sales down low single digits, about neutral currency impact, adjusted operating margin to contract versus last year, tariff impact of about $150 million annualized gross and below that in 2025, and adjusted diluted EPS of $1.00 to $1.05 including a low-single-digit currency drag.
Kirk Perry framed the quarter as below expectations and said the company must move with urgency, simplify the portfolio, and sharpen execution. He emphasized consumer-centric brand building, better e-commerce execution, fewer and bigger innovation bets, and a more choiceful allocation of resources to the biggest brands, markets, and initiatives. His tone was urgent but confident, repeatedly saying the issues are fixable and that the team has turned around similar businesses before.
Amit Banati said the company has healthy gross margins but sees room to expand margins over time through supply chain productivity, procurement, network optimization, planning, and digitization. He also pointed to SG&A above peer benchmarks because of separation-related costs, plus opportunities to improve working capital and cash conversion. On the quarter, he cited the 4.2% organic sales decline, 60.9% gross margin, 22.7% adjusted operating margin, and $0.29 adjusted EPS, and said Q2 weakness came from softer categories, seasonal and inventory issues, U.S. pricing actions, and FX.
Analysts focused on the timing and scope of the turnaround, especially how much of the complexity could be reduced quickly versus through strategic portfolio changes. Management said the Board review is broad and ongoing, but it is too early to specify restructuring actions or cash costs; the near-term focus is on removing obvious SKU complexity, improving e-commerce, and concentrating on the biggest brands and markets. Questions also probed the outlook for the back half, and Amit said July trends still look similar to Q2, with consumption ahead of organic sales but seasons remaining weak, while Q4 should benefit from easier comparisons to last year’s trade accruals and China weakness.
Management pointed to clear pockets of strength: Tylenol has 12 consecutive quarters of U.S. share improvement, Nicorette has 7 consecutive quarters of share gains, and Neutrogena Face and OGX showed sequential or positive consumption improvement. They also said EMEA and Latin America were encouraging, global consumption in Skin Health and Beauty stabilized for the first time in more than a year, and the back half includes the most robust innovation pipeline in years. The Board’s strategic review could unlock portfolio or structural value if it leads to sharper focus.
The quarter showed a large gap between consumption and reported sales, and management said execution and share are not where they need to be. Category softness, weak allergy and sun seasons, retailer inventory swings, China timing issues, and price investments all pressured results, while July trends still looked similar to Q2. Management also acknowledged complexity, underdeveloped e-commerce, tougher conditions in North America and APAC, and margin pressure from tariffs, inflation, and strategic reinvestment.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.9%
- Shares Outstanding
- 1.92B
- Float Shares
- 1.92B
of shares held by institutions
1,053 13F filers
Buy/sell ratio 1.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for KVUE, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert Ray CisnerosHouse · CA31 | Sell | Jul 17, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Aug 5, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Gilbert Ray CisnerosHouse · CA31 | Buy | Jun 16, 26 | Filing → |
| Gilbert Ray CisnerosHouse · CA31 | Sell | Mar 13, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Mar 17, 26 | Filing → |
| Gilbert Ray CisnerosHouse · CA31 | Buy | Feb 10, 26 | Filing → |
| Gilbert Ray CisnerosHouse · CA31 | Sell | Jan 9, 26 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Oct 23, 24 | Filing → |
| Julia LetlowHouse · LA05 | Sell | Oct 1, 25 | Filing → |
| Gilbert Ray CisnerosHouse · CA31 | Buy | Nov 12, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 31, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 234.95M | ▲ 1.60M |
| Fmr LLC | 157.05M | ▲ 21.96M |
| Blackrock, Inc. | 150.83M | ▲ 5.53M |
| Vanguard Capital Management LLC | 125.31M | ▲ 890.53K |
| State Street Corp | 121.62M | ▲ 2.05M |
| Vanguard Portfolio Management LLC | 93.30M | ▲ 839.37K |
| Geode Capital Management, LLC | 52.02M | ▲ 751.10K |
| Pentwater Capital Management LP | 51.13M | ▼ 870.00K |
| Independent Franchise Partners Llp | 50.43M | ▲ 1.22M |
| Norges Bank | 46.16M | ▲ 46.16M |
| Massachusetts Financial Services Co | 44.72M | ▼ 5.03M |
| Millennium Management LLC | 36.94M | ▲ 5.14M |
Held by 1,620 ETFs
Biggest fund positions in KVUE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Wondrasch Michael | other | 66,028.99 |
| Oct 1, 26 | Wondrasch Michael | other | 66,028.99 |
| Oct 1, 26 | Wondrasch Michael | other | 21,031 |
| Sep 28, 26 | Smith Jeffrey C | other | 1,300 |
| Sep 25, 26 | Stevens Meredith | other | 1,032 |
| Sep 25, 26 | Stevens Meredith | other | 429 |
| Sep 25, 26 | Stevens Meredith | other | 1,032 |
| Sep 25, 26 | Stevens Meredith | other | 1,032 |
| Sep 25, 26 | Stevens Meredith | other | 429 |
| Sep 28, 26 | ALLISON RICHARD E JR | other | 1,300 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KVUE coverage
Recent articles, reports, and earnings notes.

Kenvue (KVUE): Turnaround Signs, But Patience Needed
Kenvue is showing early stabilization with improving margins and revenue growth, but debt, mixed segment performance, and a pending Kimberly-Clark combination keep the stock in Hold territory.

Kenvue Inc. (KVUE) slips as earnings analysis digs deeper
Kenvue Inc. (KVUE) slips after an earnings miss, but the real story is in the deeper analysis. This breakdown examines what drove the results, how management’s outlook compares with expectations, and what the numbers may signal for the stock ahead.

Kenvue Inc. (KVUE) slips as earnings misses weigh on shares
Kenvue Inc. (KVUE) slips 2.4% after reporting earnings misses, with investors reacting to weaker-than-expected results and pressure on the consumer health maker's outlook.
Want a deeper read on KVUE?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
4 Dividend Aristocrats Still Raising Their Payouts No Matter What Their Stock Price Did
247wallst.com · Oct 4
Kimberly-Clark Announces Planned Executive Transitions and Updates to Post-Closing Leadership Team
prnewswire.com · Oct 1
5 ‘Bulletproof’ Dividend Kings Boomers Should Buy Now Before the Market Shifts
247wallst.com · Sep 30
Kimberly-Clark Pays Out Almost Everything It Earns. Can the Dividend Survive the Kenvue Deal?
247wallst.com · Sep 29
Kimberly-Clark Corporation Announces Commencement of Exchange Offers and Consent Solicitations for Kenvue Notes
prnewswire.com · Sep 28
Burning a Hole in My Pocket
etftrends.com · Sep 27
Kimberly-Clark offers remedies in bid for EU approval of Kenvue deal
reuters.com · Sep 23
5 Beaten-Down Dividend Kings Ready to Roar Back in 2027 (One Yields Over 5%)
247wallst.com · Sep 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed October 2, 2026 · Live quote · Not investment advice